Table 5.
Unadjusted and adjusted hazard ratio for clinical outcome by diabetes mellitus status, proteinuria, and baseline systolic blood pressure in chronic kidney disease stage 3 or 4
| Non-DM | P interaction b | DM | P interaction b | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| UPCR < 1g/g (n = 812) | UPCR ≥1g/g (n= 380) | UPCR <1g/g (n = 459) | UPCR ≥ 1g/g (n = 480) | |||||||
| Unadjusted HR (95% CI) | Adjusted HRa (95% CI) | Unadjusted HR (95% CI) | Adjusted HRa (95% CI) | Unadjusted HR (95% CI) | Adjusted HRa (95% CI) | Unadjusted HR (95% CI) | Adjusted HRa (95% CI) | |||
| CV outcomes SBP, mm Hg | 0.92 | 0.45 | ||||||||
| 96–110 | 0.56 (0.12–2.69) | 0.42 (0.08–2.09) | 0.73 (0.19–2.78) | 0.59 (0.14–2.50) | 2.93 (0.90–9.50) | 4.40 (1.29–14.99) | 1.47 (0.44–4.89) | 1.90 (0.55–6.58) | ||
| 111–120 | Reference group | Reference group | Reference group | Reference group | Reference group | Reference group | Reference group | Reference group | ||
| 121–140 | 1.42 (0.61–3.29) | 1.33 (0.56–3.19) | 0.56 (0.24–1.31) | 0.62 (0.24–1.64) | 2.50 (0.87–7.14) | 2.70 (0.92–7.95) | 1.17 (0.54–2.54) | 0.99 (0.44–2.20) | ||
| >140 | 1.43 (0.59–3.45) | 1.49 (0.59–3.78) | 0.67 (0.30–1.51) | 0.62 (0.25–1.51) | 2.17 (0.74–6.32) | 1.87 (0.62–5.63) | 1.48 (0.71–3.07) | 1.44 (0.68–3.07) | ||
| Renal outcomes SBP, mm Hg | 0.59 | <0.01 | ||||||||
| 96–110 | 2.56 (0.69–9.55) | 1.90 (0.41–8.79) | 0.37 (0.10–1.34) | 0.27 (0.06–1.10) | 1.73 (0.29–0.33) | 1.72 (0.13–22.5) | 1.30 (0.40–4.22) | 4.07 (1.18–13.99) | ||
| 111–120 | Reference group | Reference group | Reference group | Reference group | Reference group | Reference group | Reference group | Reference group | ||
| 121–140 | 1.25 (0.40–3.92) | 1.23 (0.34–4.42) | 0.60 (0.30–1.22) | 0.74 (0.33–1.67) | 0.78 (0.15–4.04) | 0.68 (0.07–6.73) | 1.36 (0.66–2.78) | 1.90 (0.89–4.06) | ||
| >140 | 2.16 (0.70–6.62) | 2.04 (0.57–7.32) | 0.82 (0.42–1.59) | 0.74 (0.33–1.65) | 1.63 (0.35–7.62) | 3.69 (0.41–3.38) | 2.05 (1.04–4.05) | 3.27 (1.58–6.74) | ||
| Mortality SBP, mm Hg | 0.65 | 0.69 | ||||||||
| 96–110 | 1.97 (0.69–5.63) | 1.22 (0.40–3.71) | 1.21 (0.40–3.71) | 2.28 (0.61–8.58) | 1.05 (0.38–2.89) | 1.75 (0.58–5.26) | 1.12 (0.29–4.32) | 1.82 (0.45–7.41) | ||
| 111–120 | Reference group | Reference group | Reference group | Reference group | Reference group | Reference group | Reference group | Reference group | ||
| 121–140 | 1.79 (0.79–4.08) | 1.62 (0.68–3.84) | 0.87 (0.39–1.96) | 2.33 (0.87–6.23) | 0.73 (0.32–1.70) | 0.80 (0.32–1.99) | 1.03 (0.45–7.41) | 1.10 (0.45–2.70) | ||
| >140 | 1.71 (0.72–4.07) | 1.46 (0.58–3.73) | 1.04 (0.48–2.26) | 2.36 (0.94–5.93) | 0.76 (0.33–1.79) | 0.84 (0.33–2.14) | 1.19 (0.54–2.62) | 1.59 (0.68–3.72) | ||
Abbreviations: CI, confidence interval; DM, diabetes mellitus; HR, hazard ratio; SBP, systolic blood pressure; UPCR, urine protein–creatinine ratio
aFully adjusted model included age, sex, estimated glomerular filtration rate, urine protein–creatinine ratio, hemoglobin, albumin, phosphorus, total cholesterol, C-reactive protein, body mass index, smoking status, baseline congestive heart failure, myocardial infarction, cerebral vascular disease, and the use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta-blockers, alpha-blockers, and diuretics.
bDefined as categorized SBP × UPCR ≥1g/g interaction P.